The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT
Martin Bland, J., & Altman, D. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90837-8 · Cited by 47,965
(1965) · The Lancet · doi:10.1016/s0140-6736(65)91037-8 · Cited by 16,856
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Hans, C. P. (2004) · Blood · doi:10.1182/blood-2003-05-1545 · Cited by 3,703
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Rosenwald, A., Wright, G., Leroy, K., Yu, X., Gaulard, P., Gascoyne, R. D., Chan, W. C., Zhao, T., Haioun, C., Greiner, T. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20031074 · Cited by 1,101
Self-citationChambers, C. A., Kuhns, M. S., Egen, J. G., & Allison, J. P. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.565 · Cited by 998
Johnson, N. A., Slack, G. W., Savage, K. J., Connors, J. M., Ben-Neriah, S., Rogic, S., Scott, D. W., Tan, K. L., Steidl, C., Sehn, L. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0985 · Cited by 975
On the exact distribution of maximally selected rank statistics
Hothorn, T., & Lausen, B. (2003) · Computational Statistics & Data Analysis · doi:10.1016/s0167-9473(02)00225-6 · Cited by 670
Cunningham, D., Hawkes, E. A., Jack, A., Qian, W., Smith, P., Mouncey, P., Pocock, C., Ardeshna, K. M., Radford, J. A., McMillan, A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60313-x · Cited by 561
Lenz, G., & Staudt, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0807082 · Cited by 528
Mounier, N. (2003) · Blood · doi:10.1182/blood-2002-11-3442 · Cited by 513
Martelli, M., Ferreri, A. J. M., Agostinelli, C., Di Rocco, A., Pfreundschuh, M., & Pileri, S. A. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.12.009 · Cited by 456
Frigola, X., Inman, B. A., Lohse, C. M., Krco, C. J., Cheville, J. C., Thompson, R. H., Leibovich, B., Blute, M. L., Dong, H., & Kwon, E. D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0250 · Cited by 345
Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma
Stiff, P. J., Unger, J. M., Cook, J. R., Constine, L. S., Couban, S., Stewart, D. A., Shea, T. C., Porcu, P., Winter, J. N., Kahl, B. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301077 · Cited by 343
PD‐L1 expression on tolerogenic APCs is controlled by STAT‐3
Wölfle, S. J., Strebovsky, J., Bartz, H., Sähr, A., Arnold, C., Kaiser, C., Dalpke, A. H., & Heeg, K. (2011) · European Journal of Immunology · doi:10.1002/eji.201040979 · Cited by 323
Chen, Y., Wang, Q., Shi, B., Xu, P., Hu, Z., Bai, L., & Zhang, X. (2011) · Cytokine · doi:10.1016/j.cyto.2011.06.004 · Cited by 243
Sehn, L. H., Scott, D. W., Chhanabhai, M., Berry, B., Ruskova, A., Berkahn, L., Connors, J. M., & Gascoyne, R. D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.3419 · Cited by 232
Wilcox, R. A., Ristow, K., Habermann, T. M., Inwards, D. J., Micallef, I. N. M., Johnston, P. B., Colgan, J. P., Nowakowski, G. S., Ansell, S. M., Witzig, T. E., et al. (2011) · Leukemia · doi:10.1038/leu.2011.112 · Cited by 188
Xerri, L., Chetaille, B., Seriari, N., Attias, C., Guillaume, Y., Arnoulet, C., & Olive, D. (2008) · Human Pathology · doi:10.1016/j.humpath.2007.11.012 · Cited by 172
Cytokine assays: An assessment of the preparation and treatment of blood and tissue samples
Keustermans, G. C. E., Hoeks, S. B. E., Meerding, J. M., Prakken, B. J., & de Jager, W. (2013) · Methods · doi:10.1016/j.ymeth.2013.04.005 · Cited by 162
Paepe, P. D., & Wolf‐Peeters, C. D. (2006) · Leukemia · doi:10.1038/sj.leu.2404449 · Cited by 122
Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma
Atanackovic, D., Luetkens, T., & Kröger, N. M. (2013) · Leukemia · doi:10.1038/leu.2013.310 · Cited by 104
Dossus, L., Becker, S., Achaintre, D., Kaaks, R., & Rinaldi, S. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.09.001 · Cited by 103
Cited by
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen, J., Jiang, C. C., Jin, L., & Zhang, X. D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv615 · Cited by 767
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
Jiang, Y., Chen, M., Nie, H., & Yuan, Y. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1571892 · Cited by 640
Kiyasu, J., Miyoshi, H., Hirata, A., Arakawa, F., Ichikawa, A., Niino, D., Sugita, Y., Yufu, Y., Choi, I., Abe, Y., et al. (2015) · Blood · doi:10.1182/blood-2015-02-629600 · Cited by 464
PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
Goodman, A., Patel, S. P., & Kurzrock, R. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.168 · Cited by 461
Metadata
- Authors
- Rossille, D., Gressier, M., Damotte, D., Maucort-Boulch, D., Pangault, C., Semana, G., Le Gouill, S., Haioun, C., Tarte, K., Lamy, T., Milpied, N., Fest, T., du Sang, F. T. G. O.-E. D. L. E. A. M., Damaj, G., Clavert, A., Al Jijakli, A., Banos, A., Dutel, J.-L., Deconinck, E., Rodon, P., Bouabdallah, K., Soubeyran, P., Choufi, B., Maakaroun, A., Tournilhac, O., Fleury, J., Gressin, R., Maisonneuve, H., Laribi, K., Solal-Celigny, P., Moreau, P., Rossi, J.-F., Cartron, G., Morineau, N., Harousseau, J. L., Jourdan, E., Alexis, M., Dreyfus, F., Delwail, V, Cornillon, J., Garidi, R., Gyan, E., Colombat, P., & Godemer, P.
- Venue
- Leukemia
- Published
- 2014-04-15
- Volume
- 28
- Issue
- 12
- Pages
- 2367-2375
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2073125824
- Cited by
- 322
- References
- 33
- FWCI
- 19.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.